Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

OBJECTIVE—We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the F...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Scott, Russell, O'Brien, Richard, Fulcher, Greg, Pardy, Chris, d'Emden, Michael, Tse, Dana, Taskinen, Marja-Riitta, Ehnholm, Christian, Keech, Anthony
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2009
Témata:
Cardiovascular and Metabolic Risk
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2646035/
https://ncbi.nlm.nih.gov/pubmed/18984774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc08-1543
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky